Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Neurelis, Inc.

Clinicaltrial registered30 Oct 2026

Neurelis, Inc.

30 Oct 2026: Trial registered · Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
30 Oct 2026
Title
Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration
Conditions
Cerebral Cavernous Malformation
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07908134
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Neurelis, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Neurelis, Inc. in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.